0
0.5
1
1.5
2+
Death/hospitalization
71%
Improvement
Relative Risk
Death/hospitalization (b)
70%
Recovery time
29%
Recovery time (b)
29%
Casirivimab/i.. Regeneron et al. EARLY TREATMENT RCT
Is early treatment with casirivimab/imdevimab beneficial for COVID-19?
RCT 2,696 patients in the USA
Lower death/hosp. (p<0.0001) and faster recovery (p=0.0001)
c19early.org
Regeneron, Press Release, March 2021
Favors casirivimab/im..
Favors control